Immune Response in COVID-19: Sero-Diagnostic Evidence for Clinical use and Research |Biomedgrid

Serological markers have remained the mainstay of infectious disease diagnosis and treatment monitoring for last so many decades. The comfort associated with serology testing has emerged from end user understanding, availability of “Rapid Point of Care testing (POCT)” formats and most importantly decreased turnaround times (TAT). In recent times, COVID-19 has burdened the healthcare systems across the globe. Rapid and accurate diagnosis is imperative to contain this contagion in the context of case detection, contact tracing, quarantine, admissions, therapeutic assessment for convalescent sera administration and epidemiological surveys for herd immunity. Nucleic Acid Tests (NAT) evolved as an accurate and early diagnostic modality and is currently considered as the standard in SARS-CoV-2 diagnosis.